Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies
British Journal of Haematology · 2025
DOI: 10.1111/bjh.20203 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Michael R Savona und 16 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Leukemia, Myelomonocytic, Chronic, Uridine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taiho Oncology, Inc..
Abstract (Originalsprache)
DNA methyltransferase inhibitors (DNMTis) are commonly used in treating chronic myelomonocytic leukaemia (CMML); however, data from prospective studies of DNMTis in CMML are limited. The present analysis evaluated the efficacy, safety and pharmacodynamics of the oral DNMTi decitabine/cedazuridine in the subset of patients with CMML from the phase 2 and 3 trials, which led to the approval of this agent for myelodysplastic syndromes and CMML in the United States and Canada. Potential prognostic factors also were analysed. In all, 34 patients with CMML were screened and 33 were treated. Most patients (76% [ n = 25]) had myelodysplastic type‐CMML and 77% ( n = 24/31 with DNA available for sequencing) had intermediate‐2 or high‐risk disease noted by CMML‐specific prognostic scoring systems. The overall response rate was 76%, with 21% ( n = 7) of patients achieving a complete response. Nearly half of the 11 patients who were red blood cell‐transfusion dependent at baseline (46%) attained transfusion independence for ≥12 weeks, which was associated with survival. Median overall and transformation‐free survival were 35.7 and 28.3 months, respectively, and the safety profile was similar to that previously reported for decitabine. This analysis described the use of decitabine/cedazuridine in CMML from consecutive, prospective, randomised trials and illustrated a median survival of nearly 3 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
- University of Chicago and the University of Chicago Comprehensive Cancer Center, Chicago, Illinois, USA.
- Weill Cornell Medicine and New York-Presbyterian Hospital, New York, New York, USA.
- BRCR Global, Plantation, Florida, USA.
- The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
ORCID-Profile: Michael R Savona, Amer M Zeidan, Rena Buckstein, Harold N Keer, Guillermo Garcia-Manero
Förderung
- Taiho Oncology, Inc.
Zitieren
APA
Savona, M. R., Odenike, O., Roboz, G. J., Amin, H., DeZern, A. E., Griffiths, E. A., Dao, K. H., Zeidan, A. M., Bhatnagar, B., Buckstein, R., Leber, B., Keating, M. M., Ball, S., Oganesian, A., Sano, Y., Keer, H. N., & Garcia-Manero, G. (2025). Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies. British Journal of Haematology. https://doi.org/10.1111/bjh.20203
Vancouver
Savona MR, Odenike O, Roboz GJ, Amin H, DeZern AE, Griffiths EA, et al. Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies. British Journal of Haematology. 2025. doi:10.1111/bjh.20203
BibTeX
@article{Savona2025,
author = {Savona, Michael R and Odenike, Olatoyosi and Roboz, Gail J and Amin, Harshad and DeZern, Amy E and Griffiths, Elizabeth A and Dao, Kim-Hien and Zeidan, Amer M and Bhatnagar, Bhavana and Buckstein, Rena and Leber, Brian and Keating, Mary-Margaret and Ball, Somedeb and Oganesian, Aram and Sano, Yuri and Keer, Harold N and Garcia-Manero, Guillermo},
title = {Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.20203}
}
EUVIMED